Profil
Hani N.
Sabbah is the founder of G3 Pharmaceuticals, Inc. He is currently working as a Director at MateraCor, Inc.
Aktive Positionen von Hani N. Sabbah
| Unternehmen | Position | Beginn |
|---|---|---|
MateraCor, Inc.
 MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Hani N. Sabbah
| Unternehmen | Position | Ende |
|---|---|---|
G3 Pharmaceuticals, Inc.
 G3 Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology G3 Pharmaceuticals, Inc. is a development-stage biopharmaceutical company. It manufactures and develops galectin-3 biology, cardiovascular pharmaceutical and carbohydrate drugs. The company is headquartered in Lexington, MA. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
G3 Pharmaceuticals, Inc.
G3 Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology G3 Pharmaceuticals, Inc. is a development-stage biopharmaceutical company. It manufactures and develops galectin-3 biology, cardiovascular pharmaceutical and carbohydrate drugs. The company is headquartered in Lexington, MA. | Health Technology |
MateraCor, Inc.
MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Health Technology |
